GlassScriptPhysician profile
Khaled M Ismail
NPI 1467674895
$3,780.11
in general payments reported to CMS, 2019-2025
26 companies · $1,242 in 2025
The $1,242 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $160 · 2021: $62.73 · 2022: $511 · 2023: $699 · 2024: $803 · 2025: $1,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,644 · Education: $99.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,643.67 |
| Education | $99.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $506.95 | 2022-2025 | |
| Vifor Pharma, INC. | $372.04 | 2019-2023 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $294.80 | 2020-2025 | Farxiga, Lokelma |
| Alexion Pharmaceuticals, INC. | $291.44 | 2019-2025 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.04 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $224.11 | 2019-2025 | Jynarque |
| Amgen INC. | $204.89 | 2020-2025 | Tavneos, Krystexxa |
| Akebia Therapeutics INC | $170.51 | 2022-2025 | Vafseo |
| Travere Therapeutics, INC. | $166.64 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $158.74 | 2024-2025 | |
| Genzyme Corporation | $144.64 | 2020-2021 | |
| Janssen Biotech, INC. | $121.35 | 2025 | Tremfya |
| Opko Pharmaceuticals, LLC | $101.89 | 2022-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $101.45 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $93.75 | 2021-2024 | Benlysta, Jesduvroq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $93.42 | 2025 | Wegovy |
| Lundbeck LLC | $89.42 | 2019 | |
| Ardelyx, INC. | $72.60 | 2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $66.32 | 2023-2025 | Acthar, Terlivaz |
| Aurinia Pharma U.S., INC. | $55.74 | 2022-2024 | Lupkynis |
| Ani Pharmaceuticals, INC. | $52.22 | 2024-2025 | Purified Cortrophin Gel |
| Alnylam Pharmaceuticals INC. | $41.75 | 2023-2025 | Oxlumo |
| Fresenius USA Marketing, INC. | $39.48 | 2022-2023 | Korsuva, Velphoro |
| Apellis Pharmaceuticals, INC. | $31.57 | 2025 | Empaveli |
| Kite Pharma, INC. | $23.02 | 2024 | Yescarta |
| Chiesi USA, INC. | $14.33 | 2025 | Elfabrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaled Ismail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.